Heidi Anne Duerr, MPH

What are some of the challenges and triumphs in using biologics for atopic dermatitis? Abby L. Allen, RN, NP, shares insights at the American College of Allergy, Asthma and Immunology 2023 Annual Scientific Meeting.

The second full day of the American College of Allergy, Asthma and Immunology (ACAAI) 2023 Annual Scientific Meeting was filled with new data, important insights, and more.

Research at the American College of Allergy, Asthma and Immunology (ACAAI) 2023 Annual Scientific Meeting discusses the impact of an educational program on improving care.

Poster presented at American College of Allergy, Asthma and Immunology (ACAAI) 2023 Annual Scientific Meeting yields positive results for adults and children 2 years age and up.

Catch up on highlights from the American College of Allergy, Asthma and Immunology (ACAAI) 2023 Annual Scientific Meeting.

Ruchi Gupta, MD, MPH, shares tips for supporting a successful transition to college for patients with atopic dermatitis.

Program Chair Jay A. Lieberman, MD, provides a glimpse into the clinical pearls and dermatological educational opportunities presented at the ACAAI 2023 Annual Scientific Meeting.

A new study presented at this year’s American College of Allergy, Asthma and Immunology Annual Scientific Meeting highlights the need for mental health support in patients with atopic dermatitis.

New treatments and clinical insights will be shared at this year's American College of Allergy, Asthma and Immunology Annual Scientific Meeting.

What would you suggest or prescribe for these AD symptoms in a 68-year-old man? Test your knowledge and take a look at new data on AD in older patients.

What are the special considerations for treating pediatric atopic dermatitis? Test your knowledge and hear more from an expert.

A patient with atopic dermatitis presents with redness and other unusual symptoms. What's the diagnosis?

A key session at the annual meeting will share practical advice and tools to better support you and your patients.

What can you do when a medication for psoriasis yields a suboptimal response? New data presented at the 2023 AAD Annual Meeting provides valuable insight on next steps for treatment.

Promising phase 2 data for LY3041658 released during the Late-breaking Research session at the 2023 annual meeting.

Expert warns lack of proper diagnosis and complete and thorough treatment of onychomycosis can lead to an endemic issue.

Designed to address the underlying causes of DEB, the investigational topical gene therapy shows great promise to improve quality of life for patients with this rare disorder.

Expert insights on the latest issues in wounds as well as HS resources are shared at the annual meeting.

Using pooled 52-week results from TRuE-AD1 and TRuE-AD2, investigators examined how the topical JAK1/JAK 2 inhibitor affects patient feelings of skin pain, discomfort, anxiety, and depression.

After reporting initial data earlier this year, investigators presented a fuller analysis in a poster at the 2022 SDPA Annual Fall Dermatology Conference.

The greatest improvements in quality of life measures were seen in the 300 mg tralokinumab group.